INDIA – The Serum Institute of India is set to expand its portfolio of products for the Indian market with the launch of its long-awaited malaria vaccine.

Notably, the Serum Institute of India has sponsored Phase III licensure clinical trials, demonstrating its commitment to combatting malaria.

The anticipated product launch was announced on the sidelines of a press conference organized by the Miss World Organisation at the Ritz-Carlton in Pune in the western Indian state of Maharashtra.

This breakthrough is a critical step towards reducing over half a million malaria-related deaths annually and improving the health outcomes of millions of people in Africa and beyond.

Speaking at an official press conference, the Managing Director of Serum Institute of India, Dr. Cyrus Poonwalla, disclosed that the pharma major is planning to launch a vaccine for malaria at an undisclosed date this year.

After the success of the Serum Institute of India COVID-19 vaccine Covishield, for the first time in the world, SII will be launching a malaria vaccine,” said Dr. Poonawalla.

Guided by a strong commitment to improving global health, the Serum Institute of India has played a pivotal role in reducing the prices of essential vaccines.

Its multifunctional production and one-of-the-largest facility in Manjri, Pune, with an annual capacity of 4 billion doses, has saved over 30 million lives over the years.

Strikingly, the Serum Institute of India has been at the forefront of the global fight against COVID-19, delivering over 2 billion doses of the COVID-19 vaccine worldwide.

Its Covishield vaccine, which is brand the name of Oxford–AstraZeneca COVID-19 vaccine, protected significantly against COVID-19, with a higher protection rate against severe forms of the disease.

The Serum Institute of India is reportedly up its first manufacturing plant in Africa as it looks to expand globally after its success in selling its India-made COVID-19 shots.

On the other hand, the Serum Institute of India vaccine for dengue is expected to launch before the end of 2024, with its development taking up to 12 months.

The incidence of dengue has grown dramatically around the world in recent decades, with cases reported to the World Health Organization increasing from 505, 430 cases in 2000 to 5.2 million in 2019.

The World Health Organization warned that the largest number of dengue cases ever reported globally was in 2019.

The burden of dengue fever infections is increasing, accounting for 101,000 cases reported in Bangladesh, 131,000 cases in Malaysia, and 420,000 cases in the Philippines and 320, 000 cases in Vietnam in 2019.

The introduction of SSI’s vaccine for dengue will significantly contribute to pooled efforts to control and prevent the transmission of the viral disease in Asian countries and beyond.

The drug development ambition comes shortly after the World Health Organization prequalified MenFive, the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis.

According to the Serum Institute of India Private Limited (SIIPL), MenFive is a game-changer vaccine that protects against meningococcal serogroups A, C, W, Y, and X.

It is the only vaccine that prevents meningitis caused by meningococcal group X, a pathogen increasingly implicated in meningitis outbreaks in Africa.

MenFive is designed to not only prevent death from meningitis but also disability in survivors who would suffer lifelong social and economic consequences.

What’s more, the Serum Institute of India recently launched India’s first indigenously-developed quadrivalent Human Papillomavirus vaccine (qHPV) in a bid to combat HPV-linked cervical cancer in the country.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.